| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:35 UTC |
|---|
| HMDB ID | HMDB0014359 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Torasemide |
|---|
| Description | Torasemide, also known as demadex or luprac, belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups. Torasemide is a strong basic compound (based on its pKa). torasemide can be converted into torasemide through the action of the enzyme solute carrier family 22 member 6. In humans, torasemide is involved in torsemide action pathway. An N-sulfonylurea obtained by formal condensation of pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. |
|---|
| Structure | CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1 InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21) |
|---|
| Synonyms | | Value | Source |
|---|
| 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea | ChEBI | | Demadex | ChEBI | | Luprac | ChEBI | | N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide | ChEBI | | Torasemida | ChEBI | | Torasemidum | ChEBI | | Torsemide | ChEBI | | 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulphonyl)urea | Generator | | N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulphonamide | Generator | | 1-Isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea | HMDB |
|
|---|
| Chemical Formula | C16H20N4O3S |
|---|
| Average Molecular Weight | 348.42 |
|---|
| Monoisotopic Molecular Weight | 348.125611216 |
|---|
| IUPAC Name | 1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea |
|---|
| Traditional Name | torsemide |
|---|
| CAS Registry Number | 56211-40-6 |
|---|
| SMILES | CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1 |
|---|
| InChI Identifier | InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21) |
|---|
| InChI Key | NGBFQHCMQULJNZ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Pyridines and derivatives |
|---|
| Sub Class | Pyridinesulfonamides |
|---|
| Direct Parent | Pyridinesulfonamides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Pyridine-3-sulfonamide
- Dihydropyridine
- Toluene
- Sulfonylurea
- Monocyclic benzene moiety
- Hydropyridine
- Benzenoid
- Secondary ketimine
- Heteroaromatic compound
- Organic sulfonic acid or derivatives
- Organosulfonic acid or derivatives
- Sulfonyl
- Aminosulfonyl compound
- Carboximidic acid derivative
- Azacycle
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organic oxide
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Organic oxygen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 164 - 164 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.06 g/L | Not Available | | LogP | 2.3 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.86 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.1292 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.48 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 31.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1547.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 217.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 130.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 152.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 56.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 387.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 456.5 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 92.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 913.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 275.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1068.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 224.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 276.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 299.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 236.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 70.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Torasemide,1TMS,isomer #1 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)=C1 | 2953.6 | Semi standard non polar | 33892256 | | Torasemide,1TMS,isomer #1 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)=C1 | 2892.4 | Standard non polar | 33892256 | | Torasemide,1TMS,isomer #1 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)=C1 | 4339.3 | Standard polar | 33892256 | | Torasemide,1TMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)=C1 | 2932.3 | Semi standard non polar | 33892256 | | Torasemide,1TMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)=C1 | 2812.9 | Standard non polar | 33892256 | | Torasemide,1TMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)=C1 | 4353.9 | Standard polar | 33892256 | | Torasemide,1TMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C)=C1 | 2847.2 | Semi standard non polar | 33892256 | | Torasemide,1TMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C)=C1 | 2817.8 | Standard non polar | 33892256 | | Torasemide,1TMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C)=C1 | 4066.5 | Standard polar | 33892256 | | Torasemide,2TMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 2776.7 | Semi standard non polar | 33892256 | | Torasemide,2TMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 3001.4 | Standard non polar | 33892256 | | Torasemide,2TMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 3774.2 | Standard polar | 33892256 | | Torasemide,2TMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 2899.1 | Semi standard non polar | 33892256 | | Torasemide,2TMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 3071.2 | Standard non polar | 33892256 | | Torasemide,2TMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 3993.8 | Standard polar | 33892256 | | Torasemide,2TMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 2746.3 | Semi standard non polar | 33892256 | | Torasemide,2TMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 2965.8 | Standard non polar | 33892256 | | Torasemide,2TMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 3912.5 | Standard polar | 33892256 | | Torasemide,3TMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 2774.6 | Semi standard non polar | 33892256 | | Torasemide,3TMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 3236.3 | Standard non polar | 33892256 | | Torasemide,3TMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C)=C1 | 3580.2 | Standard polar | 33892256 | | Torasemide,1TBDMS,isomer #1 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3204.2 | Semi standard non polar | 33892256 | | Torasemide,1TBDMS,isomer #1 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3129.3 | Standard non polar | 33892256 | | Torasemide,1TBDMS,isomer #1 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)=C1 | 4308.6 | Standard polar | 33892256 | | Torasemide,1TBDMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3196.8 | Semi standard non polar | 33892256 | | Torasemide,1TBDMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3030.3 | Standard non polar | 33892256 | | Torasemide,1TBDMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C1 | 4325.1 | Standard polar | 33892256 | | Torasemide,1TBDMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3060.1 | Semi standard non polar | 33892256 | | Torasemide,1TBDMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3030.9 | Standard non polar | 33892256 | | Torasemide,1TBDMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)NC(C)C)[Si](C)(C)C(C)(C)C)=C1 | 4102.5 | Standard polar | 33892256 | | Torasemide,2TBDMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3219.4 | Semi standard non polar | 33892256 | | Torasemide,2TBDMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3450.4 | Standard non polar | 33892256 | | Torasemide,2TBDMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)NC(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3834.2 | Standard polar | 33892256 | | Torasemide,2TBDMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3396.3 | Semi standard non polar | 33892256 | | Torasemide,2TBDMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3520.9 | Standard non polar | 33892256 | | Torasemide,2TBDMS,isomer #2 | CC1=CC=CC(NC2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 4032.1 | Standard polar | 33892256 | | Torasemide,2TBDMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3208.5 | Semi standard non polar | 33892256 | | Torasemide,2TBDMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3389.6 | Standard non polar | 33892256 | | Torasemide,2TBDMS,isomer #3 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)NC(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3955.5 | Standard polar | 33892256 | | Torasemide,3TBDMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3434.8 | Semi standard non polar | 33892256 | | Torasemide,3TBDMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3916.0 | Standard non polar | 33892256 | | Torasemide,3TBDMS,isomer #1 | CC1=CC=CC(N(C2=CC=NC=C2S(=O)(=O)N(C(=O)N(C(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1 | 3729.6 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Torasemide GC-MS (Non-derivatized) - 70eV, Positive | splash10-001i-7922000000-38709aad9fb92fea20e1 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Torasemide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Torasemide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOF | splash10-03di-0090000000-bcaf4981571fb662df86 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOF | splash10-03di-0090000000-00cc7369c05298ea1c97 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOF | splash10-03di-0490000000-60171fe07a2f255596e3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOF | splash10-01ot-2950000000-359d6835f9bf703a0701 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOF | splash10-000t-3910000000-a5ec65a6dbedfe7a30d3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOF | splash10-0564-6900000000-051171526b146f5d076c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , negative-QTOF | splash10-03di-0190000000-1b2efe76058c7bf06b4a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOF | splash10-03di-0091000000-548edfa45514c501788d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOF | splash10-03di-0090000000-d7326b2b38380cd06e26 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOF | splash10-03di-0490000000-b9f43c4768937947d77f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOF | splash10-001i-0940000000-7b7084526f7c13bf6443 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOF | splash10-00lr-0910000000-81aa8c9ff5d9a3cd3c10 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOF | splash10-0159-0900000000-87860a9931a8414432cf | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide , positive-QTOF | splash10-03di-1590000000-1b7d966c20cec1451f6c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide , positive-QTOF | splash10-03di-0490000000-bd8b6af3fe8d0f10e117 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide , positive-QTOF | splash10-02ai-2940000000-5beb0e7e25d393903803 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide LC-ESI-QFT , positive-QTOF | splash10-03di-0390000000-314819093d7d5a1f48f4 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide 30V, Negative-QTOF | splash10-03di-0090000000-6b7078f4aeb0a9155866 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Torasemide 15V, Negative-QTOF | splash10-03di-0090000000-11bcaf88b642f06fcc7e | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Torasemide 10V, Positive-QTOF | splash10-01ot-2069000000-943a38503d89c086bae7 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Torasemide 20V, Positive-QTOF | splash10-0bt9-8191000000-b93ec223bde95bf1c738 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Torasemide 40V, Positive-QTOF | splash10-0a4l-9210000000-19f11559fea4b58be1cf | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Torasemide 10V, Negative-QTOF | splash10-0002-3269000000-93ec6053a659f34ee77f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Torasemide 20V, Negative-QTOF | splash10-06si-1490000000-5dfeefbdd22794dac739 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Torasemide 40V, Negative-QTOF | splash10-0a4l-9430000000-1d7767a4763c0a30541a | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|